

S Rod Rassekh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1439620/publications.pdf>

Version: 2024-02-01

109
papers

3,439
citations

201658

27
h-index

149686

56
g-index

112
all docs

112
docs citations

112
times ranked

5023
citing authors

#	ARTICLE	IF	CITATIONS
1	Cisplatin-induced nephrotoxicity in childhood cancer: comparison between two countries. <i>Pediatric Nephrology</i> , 2023, 38, 593-604.	1.7	4
2	Pharmacogenetic testing to guide therapeutic decision-making and improve outcomes for children undergoing anthracycline-based chemotherapy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 130, 95-99.	2.5	8
3	Medicinal cannabis in children and adolescents with autism spectrum disorder: A scoping review. <i>Child: Care, Health and Development</i> , 2022, 48, 33-44.	1.7	7
4	Perspectives of pediatric oncologists and palliative care physicians on the therapeutic use of cannabis in children with cancer. <i>Cancer Reports</i> , 2022, 5, e1551.	1.4	8
5	Urine Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 to Detect Pediatric Cisplatin-Associated Acute Kidney Injury. <i>Kidney360</i> , 2022, 3, 37-50.	2.1	6
6	Neither the "Devil's Lettuce" nor a "Miracle Cure": The Use of Medical Cannabis in the Care of Children and Youth. <i>Neuroethics</i> , 2022, 15, 1.	2.8	1
7	A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant women. <i>Biomedicine and Pharmacotherapy</i> , 2022, 148, 112684.	5.6	2
8	Clinician views on and ethics priorities for authorizing medical cannabis in the care of children and youth in Canada: a qualitative study. <i>CMAJ Open</i> , 2022, 10, E196-E202.	2.4	3
9	Abstract 5224: The PRrecision Oncology For Young peoLE (PROFYLE) Program: A national precision oncology program for children, adolescents and young adults with hard-to-cure cancer in Canada. <i>Cancer Research</i> , 2022, 82, 5224-5224.	0.9	1
10	Efficacy and safety of paediatric medicinal cannabis use: A scoping review. <i>Paediatrics and Child Health</i> , 2021, 26, 228-233.	0.6	17
11	NTRK2 Fusion driven pediatric glioblastoma: Identification of oncogenic Drivers via integrative Genome and transcriptome profiling. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 1472-1477.	0.5	3
12	Histologic Correlates of Molecular Group 4 Pediatric Medulloblastoma: A Retrospective Canadian Review. <i>Pediatric and Developmental Pathology</i> , 2021, 24, 309-317.	1.0	2
13	Leptin is Associated with the Tri-Ponderal Mass Index in Children: A Cross-Sectional Study. <i>Adolescent Health, Medicine and Therapeutics</i> , 2021, Volume 12, 9-15.	0.9	0
14	Family attitudes about and experiences with medical cannabis in children with cancer or epilepsy: an exploratory qualitative study. <i>CMAJ Open</i> , 2021, 9, E563-E569.	2.4	15
15	Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 274-283.	5.6	41
16	Trametinib therapy for children with neurofibromatosis type 1 and life-threatening plexiform neurofibroma or treatment-refractory low-grade glioma. <i>Cancer Medicine</i> , 2021, 10, 3556-3564.	2.8	17
17	Malignant Mesothelioma With <i>EWSR1-ATF1</i> Fusion in Two Adolescent Male Patients. <i>Pediatric and Developmental Pathology</i> , 2021, 24, 570-574.	1.0	13
18	Deliberations about clinical pharmacogenetic testing in pediatric oncology. <i>Personalized Medicine</i> , 2021, 18, 399-405.	1.5	2

#	ARTICLE	IF	CITATIONS
19	Vertebroplasty as a palliative treatment option for intractable pain in pediatric patients with spinal tumors. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29307.	1.5	1
20	Improving the regulation of medical cannabis in Canada to better serve pediatric patients. <i>Cmaj</i> , 2021, 193, E1596-E1599.	2.0	6
21	A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT): A Clinical Research Protocol. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812110577.	1.1	1
22	Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury. <i>Npj Precision Oncology</i> , 2021, 5, 103.	5.4	18
23	Third-generation cephalosporin-resistant urinary tract infections in children presenting to the paediatric emergency department. <i>Paediatrics and Child Health</i> , 2020, 25, 166-172.	0.6	4
24	Vincristine-induced peripheral neurotoxicity: A prospective cohort. <i>Pediatric Hematology and Oncology</i> , 2020, 37, 15-28.	0.8	16
25	Establishing a Framework for the Clinical Translation of Germline Findings in Precision Oncology. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa045.	2.9	6
26	High molecular weight adiponectin levels are inversely associated with adiposity in pediatric brain tumor survivors. <i>Scientific Reports</i> , 2020, 10, 18606.	3.3	2
27	Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR. <i>Scientific Reports</i> , 2020, 10, 12564.	3.3	69
28	42 - The Prevalence of Diabetes Mellitus in Childhood Cancer Survivors: A Systematic Review and Meta-Analysis. <i>Canadian Journal of Diabetes</i> , 2020, 44, S19.	0.8	2
29	Epidemiologic Characteristics of Acute Kidney Injury During Cisplatin Infusions in Children Treated for Cancer. <i>JAMA Network Open</i> , 2020, 3, e203639.	5.9	27
30	GSTM1 null variant associated with anthracycline-related cancer in pediatric cancer. <i>Cancer</i> , 2020, 126, 3926-3928.	4.1	1
31	Circulating leptin levels are associated with adiposity in survivors of childhood brain tumors. <i>Scientific Reports</i> , 2020, 10, 4711.	3.3	9
32	Waning Vaccine Immunity and Vaccination Responses in Children Treated for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study. <i>Clinical Infectious Diseases</i> , 2020, 71, e439-e448.	5.8	6
33	LGG-19. SPINAL LOW-GRADE GLIOMAS IN CANADIAN CHILDREN: A MULTI-CENTRE RETROSPECTIVE REVIEW. <i>Neuro-Oncology</i> , 2020, 22, iii369-iii370.	1.2	0
34	Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 402-410.	4.7	56
35	Urgent need for EBMM in pediatric oncology: Evidence based medical marijuana. <i>Pediatric Hematology and Oncology</i> , 2019, 36, 253-254.	0.8	2
36	Therapeutic Implication of Genomic Landscape of Adult Metastatic Sarcoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-25.	3.0	12

#	ARTICLE	IF	CITATIONS
37	Comparative Tumor RNA Sequencing Analysis for Difficult-to-Treat Pediatric and Young Adult Patients With Cancer. <i>JAMA Network Open</i> , 2019, 2, e1913968.	5.9	38
38	Pediatric oncology and stem cell transplant patients with healthcare-associated <i>Clostridium difficile</i> infection were already colonized on admission. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27604.	1.5	16
39	ALK-Positive Lung Adenocarcinoma Arising in an Adolescent Treated for Relapsed Neuroblastoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, e132-e135.	1.1	2
40	Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings, and Future Avenues of Research. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 350-359.	4.7	24
41	Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27540.	1.5	4
42	The whole genome landscape of adult metastatic sarcoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3137-3137.	1.6	0
43	Application of genomics to identify therapeutic targets in recurrent pediatric papillary thyroid carcinoma. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002568.	1.2	14
44	Birth weight and body mass index z-score in childhood brain tumors: A cross-sectional study. <i>Scientific Reports</i> , 2018, 8, 1642.	3.3	2
45	An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26887.	1.5	7
46	High incidence of acute kidney injury during chemotherapy for childhood acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26915.	1.5	10
47	Reply to: Comment on: Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27106.	1.5	1
48	Overweight, obesity and adiposity in survivors of childhood brain tumours: a systematic review and meta-analysis. <i>Clinical Obesity</i> , 2018, 8, 55-67.	2.0	29
49	Tumor Variant Identification That Accounts for the Unique Molecular Landscape of Pediatric Malignancies. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky079.	2.9	8
50	Comparative RNA-Sequencing Analysis Benefits a Pediatric Patient With Relapsed Cancer. <i>JCO Precision Oncology</i> , 2018, 2, 1-16.	3.0	12
51	Tri-ponderal mass index in survivors of childhood brain tumors: A cross-sectional study. <i>Scientific Reports</i> , 2018, 8, 16336.	3.3	11
52	Clinical significance in pediatric oncology randomized controlled treatment trials: a systematic review. <i>Trials</i> , 2018, 19, 539.	1.6	6
53	Long-term Outcomes and Complications in Pediatric Ewing Sarcoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 423-428.	1.3	55
54	Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2017, 4, 205435811769033.	1.1	15

#	ARTICLE	IF	CITATIONS
55	The effectiveness of interventions to treat hypothalamic obesity in survivors of childhood brain tumours: a systematic review. <i>Obesity Reviews</i> , 2017, 18, 899-914.	6.5	10
56	Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1143-1145.	2.4	13
57	Adiposity in childhood brain tumors: A report from the Canadian Study of Determinants of Endometabolic Health in Children (CanDECIDE Study). <i>Scientific Reports</i> , 2017, 7, 45078.	3.3	9
58	Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits. <i>Scientific Reports</i> , 2017, 7, 10574.	3.3	20
59	Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review. <i>Pediatric Blood and Cancer</i> , 2017, 64, 81-88.	1.5	41
60	Management of germline findings revealed throughout the course of tumor-normal whole genome sequencing in oncology.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13113-e13113.	1.6	0
61	MB-91 OUTCOMES FOR YOUNG CHILDREN WITH BRAIN TUMOURS TREATED ACCORDING TO THE HEAD START PROTOCOLS: A SINGLE-CENTRE EXPERIENCE. <i>Neuro-Oncology</i> , 2016, 18, iii117.4-iii118.	1.2	0
62	Outcome of young children with high-grade glioma treated with irradiation avoiding intensive chemotherapy regimens: Final report of the Head Start II and III trials. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1806-1813.	1.5	29
63	Hypotension associated with ingestion of cannabinoids in two children with cancer. <i>Cmaj</i> , 2016, 188, 596-597.	2.0	8
64	Case 2: Early-onset Liver Failure With Palpable Abdominal Mass in a Neonate. <i>NeoReviews</i> , 2016, 17, e624-e626.	0.8	0
65	Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 683-695.	2.4	188
66	ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1051-1061.	3.7	139
67	Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 423-431.	2.0	47
68	Abstract PR14: Harnessing the power of big data to advance pediatric cancer care. , 2016, , .		0
69	Cisplatin Nephrotoxicity and Longitudinal Growth in Children With Solid Tumors. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT_Overlo</i>	1.0	25
70	Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. <i>Journal of Physical Education and Sports Management</i> , 2015, 1, a000570.	1.2	92
71	Evolution of a Pediatric Primary Cerebral ALK-1-Positive Anaplastic Large Cell Lymphoma on Serial MRI. <i>Pediatric Neurosurgery</i> , 2015, 50, 145-151.	0.7	7
72	Genetic variants in <i>SLC22A17</i> and <i>SLC22A7</i> are associated with anthracycline-induced cardiotoxicity in children. <i>Pharmacogenomics</i> , 2015, 16, 1065-1076.	1.3	95

#	ARTICLE	IF	CITATIONS
73	A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. <i>Nature Genetics</i> , 2015, 47, 1079-1084.	21.4	214
74	High-Dose Chemotherapy/Stem Cell Transplantation (HDSCT). , 2015, , 227-235.		0
75	Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. <i>Pharmacogenomics Journal</i> , 2014, 14, 160-170.	2.0	29
76	Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. <i>Pediatric Blood and Cancer</i> , 2014, 61, 393-400.	1.5	79
77	Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 253-253.	4.7	20
78	Diagnostic Value of Next-Generation Sequencing in an Unusual Sphenoid Tumor. <i>Oncologist</i> , 2014, 19, 623-630.	3.7	20
79	Vincristine and fine motor function of children with acute lymphoblastic leukemia. <i>Canadian Journal of Occupational Therapy</i> , 2014, 81, 256-264.	1.3	10
80	Intraâ€œarterial methylprednisolone for severe steroid refractory gastrointestinal graftâ€œversusâ€œhost disease. <i>Pediatric Blood and Cancer</i> , 2014, 61, 2321-2323.	1.5	4
81	Cancer Pharmacogenomics in Children. , 2014, , 77-92.		0
82	Response to â€œEvaluation of Pharmacogenetic Markers to Predict the Risk of Cisplatin-Induced Ototoxicityâ€œ. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 158-158.	4.7	2
83	Growing teratoma syndrome in intracranial non-germinomatous germ cell tumors (iNGGCTs): a risk for secondary malignant transformationâ€œa report of two cases. <i>Child's Nervous System</i> , 2014, 30, 953-957.	1.1	13
84	Genetic Markers of Cisplatin-Induced Hearing Loss in Children. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 296-298.	4.7	7
85	<i>VKORC1</i> and <i>CYP2C9</i> genotypes are predictors of warfarinâ€œrelated outcomes in children. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1055-1062.	1.5	36
86	Outcome of infants and young children with newly diagnosed ependymoma treated on the â€œHead Startâ€œIII prospective clinical trial. <i>Journal of Neuro-Oncology</i> , 2013, 113, 285-291.	2.9	60
87	Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin-Induced Hearing Loss in Children. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 243-251.	4.7	109
88	Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children. <i>Cancer Research</i> , 2013, 73, 6734-6744.	0.9	79
89	Comparative Genomic Hybridization of Wilmsâ€™ tumor. <i>Methods in Molecular Biology</i> , 2013, 973, 249-265.	0.9	1
90	Cancer Pharmacogenomics in Children: Research Initiatives and Progress to Date. <i>Paediatric Drugs</i> , 2013, 15, 71-81.	3.1	8

#	ARTICLE	IF	CITATIONS
91	Prenatal Presentation of Fronto-orbital Congenital Infantile Fibrosarcoma. JAMA Ophthalmology, 2013, 131, 965.	2.5	6
92	Validation of variants in <i>SLC28A3</i> and <i>UGT1A6</i> as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatric Blood and Cancer, 2013, 60, 1375-1381.	1.5	166
93	Antidepressant use among survivors of childhood, adolescent and young adult cancer: A report of the childhood, adolescent and young adult cancer survivor (CAYACS) research program. Pediatric Blood and Cancer, 2013, 60, 816-822.	1.5	44
94	Pharmacogenomics of vincristine-induced neurotoxicity in pediatric cancer patients. FASEB Journal, 2013, 27, 666.3.	0.5	0
95	Possible differentiation of cerebral glioblastoma into pleomorphic xanthoastrocytoma: an unusual case in an infant. Journal of Neurosurgery: Pediatrics, 2012, 9, 517-523.	1.3	16
96	Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children. Journal of Clinical Oncology, 2012, 30, 1422-1428.	1.6	341
97	Platinum-Induced Ototoxicity in Children: A Consensus Review on Mechanisms, Predisposition, and Protection, Including a New International Society of Pediatric Oncology Boston Ototoxicity Scale. Journal of Clinical Oncology, 2012, 30, 2408-2417.	1.6	298
98	Atypical Teratoid Rhabdoid Tumors (ATRTs): The British Columbia's Children's Hospital's Experience, 1986-2006. Brain Pathology, 2012, 22, 625-635.	4.1	29
99	Economic impact of a genetic test for cisplatin-induced ototoxicity. Pharmacogenomics Journal, 2012, 12, 205-213.	2.0	21
100	SEVERE GENITAL ULCERATION IN AN ACUTE EPSTEIN-BARR VIRUS INFECTION. Pediatric Infectious Disease Journal, 2011, 30, 176-178.	2.0	7
101	Nephrotic syndrome developing during induction chemotherapy for childhood acute lymphoblastic leukemia. Clinical and Experimental Nephrology, 2011, 15, 410-413.	1.6	1
102	Pathology, genetics and cytogenetics of Wilms™ tumour. Pathology, 2011, 43, 302-312.	0.6	29
103	Childhood, adolescent, and young adult cancer survivors research program of British Columbia: Objectives, study design, and cohort characteristics. Pediatric Blood and Cancer, 2010, 55, 324-330.	1.5	36
104	Abnormal liver transaminases and conjugated hyperbilirubinemia at presentation of acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2010, 55, 434-439.	1.5	28
105	Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nature Genetics, 2009, 41, 1345-1349.	21.4	287
106	In Vitro Inferiority of Ceftazidime Compared With Other Î²-lactams for Viridans Group Streptococcus Bacteremia in Pediatric Oncology Patients. Journal of Pediatric Hematology/Oncology, 2009, 31, 267-269.	0.6	7
107	Screening for submicroscopic chromosomal rearrangements in Wilms tumor using whole-genome microarrays. Cancer Genetics and Cytogenetics, 2008, 182, 84-94.	1.0	22
108	Genotypic Approaches to Therapy in Children: A National Active Surveillance Network (GATC) to Study the Pharmacogenomics of Severe Adverse Drug Reactions in Children. Annals of the New York Academy of Sciences, 2007, 1110, 177-192.	3.8	28

#	ARTICLE	IF	CITATIONS
109	Functional Deterioration following Placode Untethering in Myelomeningocele. Pediatric Neurosurgery, 1998, 28, 57-62.	0.7	13